Universty Hospital Toulouse Cardiology
Toulouse, 31059, France
NCT Number: NCT01548508
The purpose of the study is to test the efficacy of the Functionnal ElectromyoStimulation (FES) of lower limbs in advanced chronic heart failure. The hypothesis is that FES treatment could improve functional exercise capacity.
Looking for future studies?
Notify Me18 year–85 year
All sexes
Interventional
Not applicable
Toulouse, 31059, France
Advanced Chronic Heart Failure (ACHF) is a severe and frequent disease inducing a strong limitation of exercise capacity and a poor quality of life. Hospitalisation for cardiac decompensation is frequent and could alter their incapacities because of muscular deconditionning. Tradionnal aerobic rehabilitation exercises fighting against this deconditionning are not relevant in these patients because of dyspnea.
In litterature, Functionnal Electrostimulation (FES) has been tested in stable Chronic Heart Failure (NYHA I to III), far from decompensation. Several authors showed the same improvements than those obtained with conventionnal rehabilitation on aerobic capacities (peak VO2, 6 minutes walking test) and quality of life.
The originality of this study is to test FES soon after acute heart decompensation in ACHF patients. This type of rehabilitation could represent in the future an alternative to conventionnal rehabilitation until the patients could be able to do aerobic exercise.
60 patients will be randomised between two groups, the firsth receiving FES (treatment group), the second receiving skin electrostimulation in the same place without muscular contraction (Sham group). Patient and evaluator do not know what type of stimulation they have. These treatments spread over six weeks, five days per seven. They are began in rehabilitation unit then continued at home.
The principal criteria of judgement of FES efficacy is peak VO2 after the protocol. Secondary criteria are distance to the six minutes walking test, muscular strengh of quadriceps, the muscle mass measured by Dual energy X-ray absorptiometry (DEXA), inflamatory dosage (TNF alpha, IL-1, IL-6, CRP), rest value of Muscle sympathetic nerve activity, score to Minnesota questionnaire and fuctionnal independance.
The attempted results are an significative improvement of aerobic capacity(peak VO2 and six minutes walking test) and the others secondary criteria in FES group compared with Sham group.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Functionnal ElectroStimulation on lower limbs, 1h per day, 5 days per 7, during 6 weeks
SHAM on lower limbs, 1h per day, 5 days per 7, during 6 weeks
Time frame: change between baseline and 60 days after the Functional Electromyo Stimulation
Time frame: change between baseline and 60 days after the Functional Electromyo Stimulation
Time frame: change between baseline and 60 days after the Functional Electromyo Stimulation
Time frame: change between baseline and 60 days after the Functional Electromyo Stimulation
Time frame: change between baseline and 60 days after the Functional Electromyo Stimulation
Time frame: change between baseline and 60 days after the Functional Electromyo Stimulation
Time frame: change between baseline and 60 days after the Functional Electromyo Stimulation
Time frame: change between baseline and 60 days after the Functional Electromyo Stimulation
Time frame: change between baseline and 60 days after the Functional Electromyo Stimulation
Time frame: change between baseline and 60 days after the Functional Electromyo Stimulation
Time frame: change between baseline and 60 days after the Functional Electromyo Stimulation
Time frame: change between baseline and 60 days after the Functional Electromyo Stimulation
University Hospital, Toulouse
Other
Acronym: EMSICA
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05633784
Behavior, Chronic Heart Failure
Seriate, Bergamo, Italy
View Trial DetailsNCT04575428
Behavior, Cardiovascular Diseases
Durham, North Carolina, United States
View Trial DetailsNCT04698954
Behavior, Cardiovascular Diseases
Nijmegen, Gelderland, Netherlands
View Trial DetailsNCT02223624
Behavior, Cardiovascular Diseases
Epping, Victoria, Australia
View Trial Details